Picture this: a huge house is being guarded by multiple security guards. Now imagine your body is that house, and the ...

Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

Dr. Veena Joy shares her path to industry, advances in autoimmune diagnostics, CAR-T potential, health economics, and equity in women's health.

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

You may already be incorporating its key principles.

A reanalysis of twin data from Denmark and Sweden suggests that how long we live now depends roughly equally on the genes we ...

Advanced Integrated Health highlights a root-cause approach to care, helping patients address lifestyle-driven chronic ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.

Maygen Steed tells PEOPLE she still has "nightmares" about the day her daughter was diagnosed with diabetes ...